O. Rascol, K. Sieradzan, Hélène Peyro‐Saint‐Paul
Jul 1, 1998
Citations
0
Influential Citations
35
Citations
Quality indicators
Journal
Movement Disorders
Abstract
We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha‐2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.